The historical rank and industry rank for Medicamen Biotech's OCF Margin % or its related term are showing as below:
BOM:531146'
s OCF Margin % Range Over the Past 10 Years
Min: -16.77 Med: -0.13 Max: 11.33
Current: -16.77
During the past 13 years, the highest OCF Margin % of Medicamen Biotech was 11.33%. The lowest was -16.77%. And the median was -0.13%.
BOM:531146's OCF Margin % is ranked worse than 85.71% of 959
companies
in the Drug Manufacturers industry
Industry Median: 9.95
vs BOM:531146: -16.77
Medicamen Biotech OCF Margin % Related Terms
Medicamen Biotech OCF Margin % Historical Data
* Premium members only.
The historical data trend for Medicamen Biotech's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medicamen Biotech's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicamen Biotech OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medicamen Biotech's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Medicamen Biotech's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medicamen Biotech (BOM:531146) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Medicamen Biotech and its competitors. According to the industry distribution chart, Medicamen Biotech ranks #822 out of 959 companies in the Drug Manufacturers industry, placing it in the top 85.7%.
Is Medicamen Biotech's OCF Margin % too high?
Medicamen Biotech's current OCF Margin % is 0.00%. Based on the distribution chart, Medicamen Biotech ranks #822 out of 959 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medicamen Biotech has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medicamen Biotech's OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medicamen Biotech ranks #822 out of 959 companies for OCF Margin %. This places Medicamen Biotech in the lower half of its industry. The industry median OCF Margin % is 9.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.95, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Medicamen Biotech and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicamen Biotech's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicamen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Medicamen Biotech (BOM:531146) is currently considered Possible Value Trap. The stock's GF Value™ is ₹505.76, compared to a current price of ₹229.65 — trading 54.6% below its estimated fair value. The current OCF Margin % is 0.00%. Medicamen Biotech's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Medicamen Biotech (BOM:531146), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicamen Biotech (BOM:531146) Overvalued in 2026?
Based on GuruFocus' analysis, Medicamen Biotech stock appears to be undervalued.
The current stock price of ₹229.65 is trading 54.6% below its estimated GF Value™ of ₹505.76.
GuruFocus considers Medicamen Biotech to be Possible Value Trap.
Key valuation signals for BOM:531146:
OCF Margin %: 0.00%
GF Value™: ₹505.76 vs. price of ₹229.65 (54.6% below fair value)
No single metric tells the full story. See the BOM:531146 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicamen Biotech Ltd is an Indian based pharmaceutical company. The company is engaged in developing and manufacturing Pharmaceuticals formulations products. It manufactures Tablets, Capsules, Oral liquids, Dry syrups, Ointments, and Oral rehydration solution. It generates revenue from the sale of pharmaceutical products.
62GF Score
Get the complete analysis for BOM:531146
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531146 has been successfully added to your 
